Repurposing auranofin to treat TP53-mutated or PTEN-deleted refractory B-cell lymphoma

Blood Cancer J. 2019 Nov 28;9(12):95. doi: 10.1038/s41408-019-0259-8.

Authors

Jeffrey Wang¹, Jacqueline Wang², Elyse Lopez¹, Hui Guo¹, Hui Zhang¹, Yang Liu¹, Zhihong Chen¹, Shengjian Huang¹, Shouhao Zhou³, Angela Leeming¹, R J Zhang¹, Dayoung Jung¹, Hannah Shi¹, Hadley Grundman¹, Darian Doakes¹, Kathleen Cui¹, Changying Jiang¹, Makhdum Ahmed¹, Krystle Nomie¹, Bingliang Fang², Michael Wang^{1

4}, Yixin Yao¹, Liang Zhang⁵

Affiliations

¹ Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
² Department of Thoracic Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
³ Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁵ Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. liazhang@mdanderson.org.

No abstract available

Publication types

Letter
Research Support, N.I.H., Extramural

MeSH terms

Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Apoptosis / drug effects
Auranofin / pharmacology*
Auranofin / therapeutic use
Caspases / metabolism
Cell Line, Tumor
Cell Survival / drug effects
DNA Damage
Drug Repositioning
Drug Resistance, Neoplasm
Humans
Lymphoma, B-Cell / drug therapy
Lymphoma, B-Cell / genetics*
Lymphoma, B-Cell / metabolism
Lymphoma, B-Cell / pathology*
Mutation*
PTEN Phosphohydrolase / genetics*
Reactive Oxygen Species
Tumor Suppressor Protein p53 / genetics*

Substances

Antineoplastic Agents
Reactive Oxygen Species
TP53 protein, human
Tumor Suppressor Protein p53
Auranofin
PTEN Phosphohydrolase
PTEN protein, human
Caspases

Grants and funding